Topical Local Anesthetics

Increased risk of Torsade de Pointes. Avoid concomitant use.

Serious dose-related cardiac arrhythmias may occur if preparations containing vasoconstrictor are used during or following administration.

Serious dose-related cardiac arrhythmias may occur if preparations containing vasoconstrictor are used during or after administration.

Serious dose-related cardiac arrhythmias may occur if MARCAINE WITH EPINEPHRINE is used during or following potent inhalation anesthetic administration.

CNS depressants that increase risk of respiratory depression, profound sedation, coma, and death with concomitant buprenorphine use.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

General anesthetics may enhance effects causing increased CNS depression.

Butalbital causes increased CNS depression when combined with general anesthetics.

CNS depressant effects increase risk of respiratory depression, profound sedation, coma, and death.

Administration with nitrous oxide/oxygen for >30 minutes may prolong duration of action and potentiate neuromuscular blockade. Monitor with peripheral nerve stimulator.

Serious dose-related cardiac arrhythmias may occur if preparations containing vasoconstrictor epinephrine are used during or following potent inhalation anesthetic administration.

Concomitant use may increase risk of sudden blood pressure and heart rate increase during surgery. Avoid use on day of surgery.

Concurrent use may result in arrhythmias.

Depressed cardiac contractility, conductivity, and automaticity as well as vascular dilation.

Can sensitize the myocardium to dopamine effects and produce ventricular arrhythmias and hypertension.

Neuromuscular blockade and respiratory paralysis possible when aminoglycosides administered to patients receiving anesthetics.

Haloperidol may potentiate CNS depressants, increasing risk of enhanced CNS depression.

Hyaluronidase hastens onset and shortens duration of effect of local anesthetics, increasing incidence of systemic reactions due to wider spread and increased absorption.

Hyaluronidase hastens onset and shortens duration of effect; increases incidence of systemic reactions due to wider spread and increased absorption.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death; reserve for patients where alternatives are inadequate.

Serious dose-related cardiac arrhythmias may occur if preparations containing vasoconstrictor are used during or following potent inhalation anesthetic administration.

Additive CNS depression increasing risk of hypotension, respiratory depression, profound sedation, coma, and death.

Serious dose-related cardiac arrhythmias may occur if lidocaine solutions containing epinephrine are used during or following administration.

Serious dose-related cardiac arrhythmias may occur when epinephrine-containing preparations are used during or following potent inhalation anesthetics.

Serious dose-related cardiac arrhythmias may occur if preparations containing vasoconstrictor such as epinephrine are used during or following potent inhalation anesthetics.

Produces increased CNS-depressant effects including respiratory depression and sedation.

Serious dose-related cardiac arrhythmias may occur if preparations containing vasoconstrictor are used during or following potent inhalation anesthetic administration.

Anesthesia may potentiate the action of Mecamylamine HCl.

Serious cardiac arrhythmias may occur if preparations containing vasoconstrictors are employed during or following their administration.

CNS depressant effect increases risk of respiratory depression, profound sedation, coma, and death.

Concomitant use may increase risk of sudden blood pressure and heart rate increase during surgery. Avoid use on day of surgery.

Concomitant use may increase risk of sudden blood pressure and heart rate increase during surgery. Avoid use on day of surgery.

Serious dose-related cardiac arrhythmias may occur if preparations containing epinephrine are used during or following potent inhalation anesthetics.

Some inhalation anesthetics may enhance the cardiodepressant effect of metoprolol.

CNS depressants with additive effects increasing risk of hypotension, respiratory depression, and profound sedation.

Exaggeration of hypotension induced by general anesthetics when administered concurrently with nadolol.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Additive CNS depression with potential respiratory depression, hypotension, profound sedation, or coma. Dose reduction recommended.

Concomitant use increases risk of hypotension, respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Promethazine may increase, prolong, or intensify the sedative action of general anesthetics; avoid or use reduced dosage.

Promethazine may increase, prolong, or intensify sedative action of general anesthetics.

Should be used cautiously or avoided during pyridostigmine treatment due to interference with neuromuscular transmission.

CNS depressants increase risk of hypotension, respiratory depression, profound sedation, coma, and death.

May enhance rocuronium bromide activity and neuromuscular blockade.

Concomitant use may increase the risk of sudden blood pressure and heart rate increase during surgery.

Produces additive CNS-depressant effects when co-administered with temazepam.

Serious dose-related cardiac arrhythmias may occur if preparations containing vasoconstrictor are used during or following potent inhalation anesthetics.

Concomitant administration associated with erythema, histamine-like flushing, and anaphylactoid reactions.

Both inhalation anesthetics and verapamil depress cardiovascular activity by decreasing calcium ion movement. Concurrent use requires careful titration to avoid excessive cardiovascular depression.

May enhance CNS depressant effects, causing increased CNS depression.

Additive CNS depressant effects when combined with dihydrocodeine; dose reduction of one or both agents recommended.

Possibility of additive or potentiating effect with CNS depressants.

Possibility of additive or potentiating CNS depressant effect with brimonidine.

CNS depressant with potential for additive or potentiating effect when used with brimonidine tartrate ophthalmic solution.

CNS depressant with possibility of additive or potentiating effect on central nervous system depression.

CNS depressant; may result in additive or potentiating effect with brimonidine on the central nervous system.

Potential additive or potentiating effect with CNS depressants. Specific interaction studies not conducted.

Toxic effects are additive; concomitant use requires caution with monitoring for neurologic and cardiovascular effects from local anesthetic systemic toxicity.

Toxic effects are additive. Monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity.

General anesthetics may enhance the effects of butalbital and acetaminophen, causing increased CNS depression.

General anesthetics may have enhanced effects when combined with butalbital and acetaminophen, causing increased CNS depression.

General anesthetics may have enhanced effects, causing increased CNS depression.

Anesthetics may result in additive or potentiating CNS depressant effects with YUVEZZI.

Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics, including sensory and motor blockade.

Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics, including both sensory and motor blockade.

Topical local anesthetics suppress flare responses and should be avoided at skin test sites.

May potentiate or be potentiated by diazepam action. Careful consideration should be given when combining.

Additive or potentiating CNS depressant effects; droperidol dose should be reduced when used concomitantly.

CNS depressants; haloperidol may potentiate their effects and enhance CNS depression.

May suppress the flare responses to histamine and should be avoided at skin test sites.

Additive CNS depressant effects; reduced dosage of hydromorphone recommended to avoid excessive effects.

When used concomitantly with other local anesthetic products, the total amount absorbed from all formulations must be considered to avoid toxicity.

When used concomitantly with other products containing local anesthetic agents, the total absorbed amount from all formulations must be considered to avoid toxicity.

When used concomitantly with lidocaine hydrochloride/menthol, the total amount absorbed from all formulations must be considered to avoid toxicity.

When lidocaine patch 5% is used concomitantly with other products containing local anesthetic agents, the total amount absorbed from all formulations must be considered.

When used concurrently with other local anesthetic products, total absorbed amount from all formulations must be considered.

When used concurrently with other local anesthetic products, total absorbed amount from all formulations must be considered to avoid toxicity.

Additive CNS depressant effects when used with magnesium; dosage should be adjusted with caution.

Additive CNS depressant effects may occur; dosage adjustment needed when used concomitantly with magnesium sulfate.

Patients may require reduced doses of anesthetics when on methyldopa. Hypotension during anesthesia can be controlled by vasopressors.

Some inhalation anesthetics may enhance the cardiodepressant effect of metoprolol.

Phenylephrine may potentiate the cardiovascular depressant effects of inhalation anesthetic agents.

Promethazine may increase, prolong, or intensify sedative action; agents should be avoided or administered in reduced dosage.

Administration should be adjusted with caution in patients receiving magnesium-containing solutions due to additive central depressive effect.

Hypotensive effect of sodium nitroprusside is augmented by inhaled anesthetics.

Effects of preanesthetic and anesthetic agents may be potentiated when given with triamterene.

Effects may be potentiated when given together with triamterene.

Concomitant administration has been associated with erythema and histamine-like flushing.